Johnson & Johnson chief figures Amazon could shake up pharma's distribution, rebates and more

As the drug pricing system undergoes changes, Amazon remains a potential player in the field. (Amazon)

There’s been plenty of speculation about Amazon's intentions in pharmaceuticals, and now Johnson & Johnson’s CEO has weighed in on how the tech giant could affect drug markets by shaking up pharma distribution and reimbursement.

Speaking with Fortune’s Susie Gharib, J&J CEO Alex Gorsky said megamergers in healthcare, such as the Aetna/CVS megamerger and Cigna’s Express Scripts buyout, demonstrate that “there is a lot of pressure in the system right now.” And as J&J knows firsthand from its consumer products business with Amazon, the retail giant's vaunted distribution efficiencies and broad consumer reach could help ease some of that pressure.

“We have conversations at all levels going on with Amazon. I think Jeff (Bezos) and as importantly Amazon is a very innovative organization, and they see this as an opportunity to make a difference," Gorsky said. "Just as we are partnering with them today in areas of our consumer products, we’ll look forward to partnering with them in the future in some of these other areas as well.” 

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

It’s clear what Amazon could offer in distribution expertise, but the company could also explore changes in reimbursement, where drugmakers have complained about growing rebates for years. 

"We all know there are inefficiencies in the current system,” he said during the interview. “So whether it’s distribution, whether it’s reimbursement, whether it’s the way that we insure, all of those are significant opportunities. At J&J, we would welcome those kind of entrants into the market.”

RELATED: As Amazon entry into pharma looms, CEOs see plenty of room for change in distribution 

The conversation comes amid a time of significant change in the U.S. drug pricing ecosystem brought about by years of attention to price increases and rebate growth. Notable developments in the field recently have been Amgen’s move to cut its list price on PCSK9 cholesterol drug Repatha by 60%, Gilead’s decision to launch authorized generics of its own drugs and mergers between PBMs and insurers.  

Amazon, for its part, has reportedly been eyeing pharmaceuticals for more than a year. In January, the company teamed up with Berkshire Hathaway and JPMorgan to form a joint venture aiming to lower healthcare costs. 

Then, in June, Amazon purchased independent pharmacy PillPack, giving it access to the startup’s pharmacy distribution system. PillPack, which packages each patient's drugs by date and time of dosing, is authorized to ship drugs in 49 states, Reuters reported at the time. In the wake of the deal, Evercore ISI analysts wrote that it's "undeniable" Amazon is entering the pharmacy industry, according to CNBC. 

Gorsky isn’t the only pharma CEO to weigh in on Amazon. Amid heated speculation about Amazon’s intentions in pharma late last year, Pfizer’s Ian Read said "any system of distribution that can cut costs and get a wide availability of products to patients is something that the whole industry would be interested in." Allergan CEO Brent Saunders said the "whole ecosystem is ripe for disruption." 

Suggested Articles

Traditional generics bigwigs Teva, Mylan, Sandoz, Amneal and Endo have lost out to a group of six competitors in terms of U.S. weekly prescriptions.

Roche’s Tecentriq scored some big wins lately, including a pair of first-in-class approvals. But in other cancers, it's decided to pull the plug.

Biosims haven't worked, experts say. Instead, it's time to for an independent body to set fair biologic prices after the drugs lose exclusivity.